Dual GIP/GLP-1 receptor agonist · FDA-approved · Weekly subcutaneous
Tirzepatide: the dual-agonist that raised the ceiling for medical weight loss.
Tirzepatide is the first FDA-approved dual agonist of the GIP and GLP-1 receptors. Marketed as Mounjaro (type 2 diabetes) and Zepbound (chronic weight management), it produced mean weight loss of 20.9% at 15 mg in SURMOUNT-1 — the largest seen with any pharmacologic monotherapy to date.
Free shipping over $150 · Pay with card or crypto
What Tirzepatide is
Tirzepatide is a 39-amino-acid linear peptide engineered by Eli Lilly. It is structurally derived from native GIP and modified for balanced affinity at both the GIP receptor and the GLP-1 receptor, with a C20 fatty-diacid moiety for once-weekly half-life.
It is approved in the U.S. as Mounjaro (type 2 diabetes, 2022) and Zepbound (chronic weight management, 2023; OSA in obesity, 2024).
Because tirzepatide was never on the FDA shortage list with the same compounding allowances late in 2024, large-scale compounded tirzepatide has been substantially curtailed. Branded product is the standard of care in the U.S.
How it works
GLP-1 receptor activation produces the appetite, gastric, and incretin effects familiar from semaglutide. GIP receptor activation in the CNS appears to further suppress appetite and may improve adipose-tissue lipid handling and energy expenditure.
The combined effect is greater weight loss than GLP-1 alone at clinically tolerable doses. GIP activity may also blunt some of the nausea associated with pure GLP-1 agonism, though GI symptoms are still the dominant side-effect class.
Like semaglutide, tirzepatide slows gastric emptying and modulates reward circuitry — reducing both meal size and the hedonic drive to snack between meals.
What patients use it for
Class-leading weight loss
SURMOUNT-1: 20.9% mean body-weight reduction at 15 mg over 72 weeks; 91% of participants achieved ≥5% weight loss; 36% achieved ≥25%.
Superior HbA1c reduction
SURPASS program: HbA1c reductions of 1.9–2.6%, with up to 86% of patients reaching A1c <7.0% at higher doses — exceeding semaglutide head-to-head in SURPASS-2.
Improved cardiometabolic markers
Reductions in triglycerides, LDL, ALT, systolic blood pressure, and waist circumference exceed those of GLP-1 monotherapy in matched populations.
Obstructive sleep apnea improvement
SURMOUNT-OSA (2024) showed ~50% reduction in apnea-hypopnea index in adults with obesity and moderate-to-severe OSA — supporting an FDA OSA indication.
Evidence summary
SURMOUNT program: SURMOUNT-1 (obesity without diabetes, NEJM 2022), SURMOUNT-2 (obesity with T2D), SURMOUNT-3 (intensive lifestyle lead-in), SURMOUNT-4 (withdrawal), SURMOUNT-5 (head-to-head vs semaglutide, 2024) — tirzepatide superior on weight endpoints.
SURPASS program: seven Phase 3 RCTs in type 2 diabetes vs placebo, semaglutide 1 mg, insulin degludec, and insulin glargine — tirzepatide superior across glycemic and weight endpoints.
SURMOUNT-OSA (Malhotra A et al., NEJM 2024): first incretin therapy approved for a sleep-medicine indication.
Dosing and clinical context
General clinical context only. Kindr Health physicians determine the appropriate dose and protocol for each patient based on history and labs. This is not a prescription or dosing recommendation.
Standard titration: 2.5 mg weekly × 4 weeks → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg weekly maintenance. Stay on each dose ≥4 weeks before increasing.
For weight management, maintenance dose is individualized; many patients respond well at 5–10 mg and do not require escalation to 15 mg.
Injection sites: abdomen, thigh, or upper arm. Same-day-each-week dosing. Missed dose may be taken within 4 days; otherwise skip and resume schedule.
Safety and contraindications
Most common side effects are GI: nausea, diarrhea, decreased appetite, constipation, vomiting. Generally titration-dependent and improve over weeks.
Boxed warning for thyroid C-cell tumors (rodent data). Contraindicated in personal or family history of medullary thyroid carcinoma or MEN-2.
Warnings: pancreatitis, gallbladder disease, hypoglycemia (mainly with sulfonylurea/insulin co-therapy), acute kidney injury from dehydration, diabetic retinopathy.
Not recommended in pregnancy. May reduce effectiveness of oral contraceptives at initiation and dose escalation — use barrier method or non-oral contraceptive for 4 weeks after each change.
Who it's typically considered for
- Adults with BMI ≥30, or ≥27 with a weight-related comorbidity (Zepbound label)
- Adults with type 2 diabetes inadequately controlled on metformin or other oral agents
- Patients with obesity and moderate-to-severe OSA (Zepbound 2024 indication)
- Patients who plateaued on semaglutide and need additional weight loss
Frequently asked questions
Is tirzepatide more effective than semaglutide?
On weight endpoints, yes — SURMOUNT-5 (2024) directly compared the two and showed superior weight loss with tirzepatide. On HbA1c, tirzepatide also outperforms semaglutide 1 mg head-to-head in SURPASS-2.
Why is tirzepatide called a "dual agonist"?
It activates two incretin receptors — GIP and GLP-1 — with balanced affinity. Pure GLP-1 agonists (semaglutide, liraglutide) act on only one. The dual mechanism is believed to drive its greater efficacy.
Can compounded tirzepatide still be prescribed?
Broad commercial compounding of tirzepatide is no longer permitted in the U.S. after FDA shortage-list resolution. Patients should use branded Mounjaro or Zepbound.
Will I regain weight if I stop?
SURMOUNT-4 showed substantial regain after withdrawal. Obesity is chronic — maintenance therapy or a structured de-escalation plan is recommended.
Is muscle loss a concern?
A meaningful fraction of weight lost on incretin therapy is lean mass. Adequate protein intake (≥1.2 g/kg/day) and resistance training during titration protect skeletal muscle.
Can tirzepatide cause hair loss?
Rapid weight loss from any cause can trigger telogen effluvium (temporary, diffuse shedding). It is typically self-limited and resolves within 3–6 months of weight stabilization.
How long do I need to take it?
Most clinicians frame tirzepatide like blood-pressure medication — long-term, with periodic re-evaluation. Stopping reliably reverses much of the benefit.
Does insurance cover Zepbound?
Coverage varies. Many commercial plans cover Zepbound for BMI criteria; Medicare does not yet cover anti-obesity medications. Mounjaro coverage is more common when there is documented type 2 diabetes.
Sources
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). NEJM (2022). — pubmed.ncbi.nlm.nih.gov/35658024
- Frías JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). NEJM (2021). — pubmed.ncbi.nlm.nih.gov/34170647
- Malhotra A et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (SURMOUNT-OSA). NEJM (2024). — pubmed.ncbi.nlm.nih.gov/38912654
- FDA prescribing information — Zepbound (tirzepatide). — www.accessdata.fda.gov/drugsatfda_docs/label/2024/217806s007lbl.pdf
Considering Tirzepatide?
A Kindr Health physician reviews every longevity intake — peptides are prescribed only when medically indicated based on your history and labs. There is no charge for the initial review.
Related peptides
Medically reviewed by Kindr Health Clinical Team
Kindr Health Inc. — Editorial & Clinical Team (physician-supervised)
NPI 1609792902 · Last reviewed: July 3, 2026
Last reviewed July 3, 2026. Compounded medications are prepared by FDA-registered 503A pharmacies and are not FDA-approved drug products. Prescriptions require a clinical evaluation; a Kindr Health physician determines eligibility. Not for use in pregnancy. This page provides educational information and is not medical advice.